A young woman in the U.S. who experienced recurrent cholestasis was later found, with the help of genetic testing,…
Margarida Maia, PhD
Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Margarida Maia, PhD
BILIARY ATRESIA
NewsBiliary atresia patient spotlighted in 2025 ALF Liver Life Walk
Domenic Frappolli, who was born with biliary atresia, was named the American Liver Foundation’s (ALF) 2025 National LIVEr Champion.
Gilead Sciences’ oral therapy seladelpar has been conditionally approved by the European Commission as a second-line therapy for…
CHOLESTASIS
NewsCombo of variants in ABCB4 gene could lead to ICP, study finds
A specific variant in the ABCB4 gene does not cause intrahepatic cholestasis of pregnancy (ICP) on its own, but…
CHOLESTASIS
NewsAI models may aid intrahepatic cholestasis of pregnancy prediction
New artificial intelligence (AI) models based on 11 possible risk factors of intrahepatic cholestasis of pregnancy (ICP) can accurately…
CHOLESTASIS
NewsLivmarli, Bylvay safely reduce pruritus in PFIC, Alagille children
Livmarli (maralixibat) and Bylvay (odevixibat) can help relieve itching, or pruritus, and reduce liver damage in children with progressive…
CHOLANGITIS
NewsThree-factor tool may predict response to UDCA in PBC: Study
A predictive tool that incorporates several blood biomarkers may help to identify primary biliary cholangitis (PBC) patients who are less…
A genetic variant unique to East Asians increases the risk of intrahepatic cholestasis of pregnancy (ICP) by more than…
CHOLANGITIS
NewsLivdelzi approved in UK as PBC treatment for certain adults
Gilead Sciences’ Livdelzi (seladelpar) has been approved in the U.K. as a treatment for adults with primary biliary…
In 2024, Liver Disease News kept readers informed aboout liver disease research, treatments, and clinical trials. Here are the 10…